DK0640128T3 - Vaccinesammensætninger indeholdende attenueret respiratorisk syncytialvirus - Google Patents

Vaccinesammensætninger indeholdende attenueret respiratorisk syncytialvirus

Info

Publication number
DK0640128T3
DK0640128T3 DK93912315T DK93912315T DK0640128T3 DK 0640128 T3 DK0640128 T3 DK 0640128T3 DK 93912315 T DK93912315 T DK 93912315T DK 93912315 T DK93912315 T DK 93912315T DK 0640128 T3 DK0640128 T3 DK 0640128T3
Authority
DK
Denmark
Prior art keywords
attenuated
virus
respiratory syncytial
syncytial virus
vaccine compositions
Prior art date
Application number
DK93912315T
Other languages
Danish (da)
English (en)
Inventor
Brian Robert Murphy
Robert Merritt Chanock
James Earl Crowe Jr
Mark Connors
Kuo-Hom Lee Hsu
Alan Robert Davis
Michael David Lubeck
Bernard Hugh Apt N- Selling
Original Assignee
American Home Prod
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod, Us Health filed Critical American Home Prod
Application granted granted Critical
Publication of DK0640128T3 publication Critical patent/DK0640128T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/01—Preparation of mutants without inserting foreign genetic material therein; Screening processes therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Vertical, Hearth, Or Arc Furnaces (AREA)
DK93912315T 1992-04-21 1993-04-20 Vaccinesammensætninger indeholdende attenueret respiratorisk syncytialvirus DK0640128T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87274692A 1992-04-21 1992-04-21
US3994593A 1993-04-09 1993-04-09
PCT/US1993/003670 WO1993021310A1 (fr) 1992-04-21 1993-04-20 Compositions de vaccins a base de virus respiratoire syncytial attenue

Publications (1)

Publication Number Publication Date
DK0640128T3 true DK0640128T3 (da) 1999-11-22

Family

ID=26716607

Family Applications (1)

Application Number Title Priority Date Filing Date
DK93912315T DK0640128T3 (da) 1992-04-21 1993-04-20 Vaccinesammensætninger indeholdende attenueret respiratorisk syncytialvirus

Country Status (18)

Country Link
US (3) US5922326A (fr)
EP (1) EP0640128B1 (fr)
JP (1) JP3883202B2 (fr)
KR (1) KR100257171B1 (fr)
AT (1) ATE181359T1 (fr)
AU (1) AU683840B2 (fr)
CA (1) CA2118509C (fr)
DE (1) DE69325370T2 (fr)
DK (1) DK0640128T3 (fr)
ES (1) ES2132233T3 (fr)
GR (1) GR3031208T3 (fr)
HU (1) HU220189B (fr)
IL (1) IL105456A (fr)
MX (1) MX9302278A (fr)
NZ (1) NZ252857A (fr)
RU (1) RU2139729C1 (fr)
UA (1) UA41315C2 (fr)
WO (1) WO1993021310A1 (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200117D0 (en) * 1992-01-06 1992-02-26 Connaught Lab Production of recombinant chimeric proteins for vaccine use
TW275632B (fr) * 1992-04-21 1996-05-11 American Cyanamid Co
US7083795B1 (en) 1993-08-06 2006-08-01 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
US7223410B1 (en) 1994-08-05 2007-05-29 Sanofi Pasteur Limited Inactivated respiratory syncytial viral vaccines
US5789229A (en) * 1994-09-30 1998-08-04 Uab Research Foundation Stranded RNA virus particles
US5716821A (en) * 1994-09-30 1998-02-10 Uab Research Foundation Prevention and treatment of respiratory tract disease
US6083925A (en) 1995-06-07 2000-07-04 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6019980A (en) * 1995-06-07 2000-02-01 Connaught Laboratories Limited Nucleic acid respiratory syncytial virus vaccines
US6689367B1 (en) 1995-09-27 2004-02-10 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated chimeric respiratory syncytial virus vaccines from cloned nucleotide sequences
US7485440B2 (en) 1995-09-27 2009-02-03 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated respiratory syncytial virus vaccines involving modification of M2 ORF2
WO1997012032A1 (fr) * 1995-09-27 1997-04-03 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Production de virus syncytial respiratoire infectieux a partir de sequences de nucleotides clones
US7846455B2 (en) 1996-07-15 2010-12-07 The United States Of America As Represented By The Department Of Health And Human Services Attenuated chimeric respiratory syncytial virus
US20050287540A1 (en) * 1995-09-27 2005-12-29 Murphy Brian R Production of attenuated negative stranded RNA virus vaccines from cloned nucleotide sequences
EP0917592A4 (fr) * 1996-04-04 2002-04-24 Univ Michigan Virus respiratoire syncytial attenue
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
AU3431397A (en) * 1996-07-12 1998-02-09 Connaught Laboratories Limited Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation
ES2345643T3 (es) 1996-07-15 2010-09-28 The Government Of The Usa, As Represented By The Department Of Health And Human Services Produccion de vacunas a base de virus respiratorio sincitial atenuado, a partir de secuencias nucleotidicas clonadas.
US6699476B1 (en) 1996-07-15 2004-03-02 Peter L. Collins Production of recombinant respiratory syncytial viruses expressing immune modulatory molecules
CA2265554A1 (fr) * 1996-09-27 1998-04-02 American Cyanamid Company Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
US7951383B2 (en) 1997-05-23 2011-05-31 The United States Of America As Represented By The Department Of Health And Human Services Attenuated parainfluenza virus (PIV) vaccines
US7201907B1 (en) 1997-05-23 2007-04-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Attenuated human-bovine chimeric parainfluenza virus(PIV) vaccines
US20030082209A1 (en) 2000-07-05 2003-05-01 Skiadopoulos Mario H. Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US7632508B2 (en) 1997-05-23 2009-12-15 The United States Of America Attenuated human-bovine chimeric parainfluenza virus (PIV) vaccines
US6410023B1 (en) 1997-05-23 2002-06-25 United States Of America Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene
FR2764903A1 (fr) * 1997-06-23 1998-12-24 Pasteur Institut Detection des infections par des paramyxovirus (virus respiratoire syncitial et virus parainfluenza) utilisant des polynucleotides codant de la proteine l
US20040005542A1 (en) 2001-06-22 2004-01-08 Krempl Christine D Respiratory syncytial virus vaccines expressing protective antigens from promotor- proximal genes
US7662397B2 (en) 1997-07-15 2010-02-16 The United States Of America As Represented By The Department Of Health And Human Services Respiratory syncytial virus vaccines expressing protective antigens from promoter-proximal genes
US6482414B1 (en) 1998-08-13 2002-11-19 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6177082B1 (en) 1998-08-13 2001-01-23 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
US6579528B1 (en) 1998-08-13 2003-06-17 The University Of Pittsburgh - Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
JP2002541785A (ja) 1999-04-13 2002-12-10 アメリカ合衆国 クローン化ヌクレオチド配列からの弱毒化キメラ呼吸系発疹ウイルスワクチンの製造
US7820182B2 (en) * 1999-07-09 2010-10-26 The United States Of America As Represented By The Department Of Health And Human Services Production of attenuated, human-bovine chimeric respiratory syncytial viruses for use in immunogenic compositions
WO2001004335A2 (fr) * 1999-07-09 2001-01-18 The Government Of The United States Of America, As Represented By The Department Of Health And Humanservices Production de vaccins a virus respiratoires syncitiaux chimeres humains-bovins attenues
AU2001249300B2 (en) 2000-04-03 2006-02-16 The University Of Pittsburgh-Of The Commonwealth System Of Higher Education Cold-adapted equine influenza viruses
WO2003028759A1 (fr) * 2001-09-28 2003-04-10 University Of South Florida Vaccin a expression genique contre le rsv
CN103540613A (zh) * 2002-04-26 2014-01-29 米迪缪尼有限公司 制备流感病毒的多质粒系统
US7465456B2 (en) * 2002-04-26 2008-12-16 Medimmune, Llc Multi plasmid system for the production of influenza virus
AU2003295339B2 (en) * 2002-09-27 2009-03-26 Medimmune, Llc Functional mutations in respiratory syncytial virus
WO2004083397A2 (fr) * 2003-03-18 2004-09-30 Wyeth Holdings Corporation Procede permettant d'accroitre les rendements de glycoproteines a surface vrs au moyen d'une souche de mutants du vrs
CA2520671C (fr) * 2003-03-28 2014-03-18 Medimmune Vaccines, Inc. Compositions contenant un virus syncytial respiratoire de la souche 9320 du sous-groupe b, et procedes associes
CA2529647C (fr) 2003-06-16 2013-08-13 Medimmune Vaccines, Inc. Hemagglutinine du virus de la grippe et variantes de la neuraminidase
BRPI0417672A (pt) * 2003-12-17 2007-03-20 Wyeth Corp processos para produzir composições de vìrus estáveis em armazenamento, composições de vìrus e imunogênicas
WO2005062820A2 (fr) 2003-12-23 2005-07-14 Medimmune Vaccines, Inc Systeme a plasmides multiples pour la production du virus de la grippe
CA2822895A1 (fr) 2004-05-25 2005-12-08 Medimmune, Llc Variantes hemagglutinine et neuraminidase de la grippe
EP2441471B1 (fr) 2005-03-08 2014-10-08 MedImmune, LLC Virus de la grippe réassortis
US7601356B2 (en) * 2006-07-21 2009-10-13 Medimmune, Llc Methods and compositions for increasing replication capacity of an influenza virus
KR101586968B1 (ko) * 2006-08-09 2016-01-20 메디뮨 엘엘씨 인플루엔자 헤마글루티닌 및 뉴라미니다제 변이체
WO2008157583A1 (fr) * 2007-06-18 2008-12-24 Medimmune, Llc Virus b de la grippe présentant des modifications du polypeptide de l'hémagglutinine
EP2069485A4 (fr) * 2007-07-13 2011-05-25 Medimmune Llc Préparation de virus d'arn à brin négatif par électroporation
BRPI0915487A2 (pt) * 2008-07-11 2017-06-27 Medimmune Inc hemaglutina de nfluenza e variantes de neuraminidase
AU2010213966B2 (en) 2009-02-12 2015-01-22 Medimmune, Llc Influenza hemagglutinin and neuraminidase variants
GB201003630D0 (en) 2010-03-04 2010-04-21 Novartis Ag Avian rotavirus
JP2015501141A (ja) 2011-10-07 2015-01-15 メディミューン，エルエルシー インフルエンザヘマグルチニン変異体
EP3875112A1 (fr) 2012-04-13 2021-09-08 The United States of America, as Represented By the Secretary, Department of Health and Human Services Vaccin vivant atténué et génétiquement stable contre le virus respiratoire syncytial et sa production
KR20150127206A (ko) * 2013-03-14 2015-11-16 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 나노입자-기재 조성물
CA2906606A1 (fr) 2013-03-14 2014-09-25 Emory University Rsv recombine avec des mutations silencieuses, vaccins, et procedes apparentes
BR112018008708A2 (pt) 2015-10-29 2018-11-06 Univ Emory rsv quimérico, composições imunogênicas e métodos de uso
RU2746280C1 (ru) * 2020-08-03 2021-04-12 Федеральное государственное бюджетное научное учреждение "Федеральный исследовательский центр фундаментальной и трансляционной медицины" (ФИЦ ФТМ) Штамм респираторно-синцитиального вируса RSV/Novosibirsk/66Hl/2018 для использования в диагностике респираторно-синцитиальной вирусной инфекции и исследования эффективности противовирусных препаратов in vitro

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4866034A (en) * 1982-05-26 1989-09-12 Ribi Immunochem Research Inc. Refined detoxified endotoxin
US4800078A (en) * 1987-05-28 1989-01-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Immunotherapeutic method of treating respiratory disease by intranasal administration of Igb
US5250298A (en) * 1988-10-07 1993-10-05 University Of Delaware Live attenuated newcastle disease virus vaccines and preparation thereof

Also Published As

Publication number Publication date
GR3031208T3 (en) 1999-12-31
EP0640128A1 (fr) 1995-03-01
DE69325370D1 (de) 1999-07-22
JPH07505891A (ja) 1995-06-29
KR100257171B1 (ko) 2000-05-15
CA2118509C (fr) 2009-05-19
IL105456A0 (en) 1993-08-18
NZ252857A (en) 1997-06-24
US5922326A (en) 1999-07-13
HUT69992A (en) 1995-09-28
ES2132233T3 (es) 1999-08-16
IL105456A (en) 1996-12-05
AU683840B2 (en) 1997-11-27
MX9302278A (es) 1994-07-29
AU4290793A (en) 1993-11-18
WO1993021310A1 (fr) 1993-10-28
RU2139729C1 (ru) 1999-10-20
KR950701382A (ko) 1995-03-23
US6284254B1 (en) 2001-09-04
JP3883202B2 (ja) 2007-02-21
HU220189B (hu) 2001-11-28
HU9403023D0 (en) 1994-12-28
US5882651A (en) 1999-03-16
RU94045898A (ru) 1996-09-20
CA2118509A1 (fr) 1993-10-28
ATE181359T1 (de) 1999-07-15
EP0640128B1 (fr) 1999-06-16
UA41315C2 (uk) 2001-09-17
DE69325370T2 (de) 1999-10-14

Similar Documents

Publication Publication Date Title
DE69325370D1 (de) Attenuierter respiratorischer synzytialvirus enthaltende impfstoff-zusammensetzungen
MA22842A1 (fr) Procede de preparation de compositions de vaccin.
CA2339089A1 (fr) Virus de la grippe equine adaptes au froid
BRPI9710363B8 (pt) partìcula de vìrus sincicial respirátorio recombinante (rsv) infeccioso atenuado, vacina para induzir proteção contra o vìrus sincicial respiratório recombinante (rsv), vetor de expressão, e, método de produção de um vìrus sincicial respiratório recombinante (rsv) infeccioso.
EE200200507A (et) Muundatud vaktsiiniaviirus Ankara (MVA), sellega nakatatud peremeesrakk ning seda sisaldav farmatseutiline kompositsioon, MVA valmistamine ja raviotstarbeline kasutamine
DK0869814T3 (da) Stabilisatorer til levende vacciner
NO20002605L (no) Sferoider, fremstillingsmetode og farmasøytiske sammensetninger
UA66744C2 (en) 5,6-dichlorobenzimidazole derivatives, methods for the preparation thereof, pharmaceutical composition and method for treatment of viral infections
TW266228B (fr)
GB9306731D0 (en) Vaccines
WO2001060849A3 (fr) Virus de la grippe equine, adapte au froid
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
WO2000057909A3 (fr) Vaccin a base de virus de dengue-2 attenue
NZ505894A (en) Methylenebisbenzaldehyde derivatives, methylidynetrisphenol derivative and pharmaceuticals thereof; useful for treating or preventing pneumovirus infection and associated diseases
WO2000057908A3 (fr) Vaccin antiviral attenue du dengue de type 1
WO2000057904A3 (fr) Vaccin a base de virus de dengue-3 attenue
AU4930001A (en) Cold-adapted equine influenza viruses
AU3439799A (en) Immunization against and treatment for infection by (h.pylori)
WO2003049670A3 (fr) Formulations d'adjuvant pour vaccins antiviraux et antibacteriens et leur procede de fabrication
HUP9700975A2 (hu) Élő, legyengített, Pasteurellaceae családba tartozó, RTX-termelő baktériumok
ES2055610T3 (es) Vacuna contra hrsv.
NO982854L (no) Nitrogenoksyd (NO) syntetase-inhibitor for Õ behandle eller forebygge type II diabetes
DK0728001T3 (da) Anvendelse af 2-aminopurinderivater til behandling og forebyggelse af humant herpesvirus 6-infektioner
NO980721L (no) Vaksiner
MX9801664A (es) Formas zwitterionicas de trovafloxacina, procedimiento para su preparacion, composiciones que las contienen y uso de las mismas.